Recent progress in understanding tumor–immune dynamics emphasizes ICIs targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PDCD1, also known as PD-1), which enhance therapeutic outcomes across several malignancies [16,21]. Here, CTLA4 is linked to neoplasm.